Cancers (Basel)
February 2025
The current standard therapy for pediatric optic pathway/hypothalamic glioma (OPHG) is systemic anticancer therapy (SAT) over surgery and radiotherapy. Nevertheless, recurrent radiological or clinical tumor progression after SAT forms a considerable challenge. Sporadic OPHGs are considered to have a higher tendency toward progression after first-line systemic anticancer therapy (SAT) compared to neurofibromatosis type-1-associated (NF1) OPHGs.
View Article and Find Full Text PDFPurpose: To examine long-term visual impairment and visual field examination (VF) after diverse treatments for paediatric optic pathway glioma (OPG), and to determine prognostic factors for long-term severe visual impairment or blindness.
Methods: A nationwide retrospective cohort study (1995-2018) was performed on paediatric OPGs that received various (successive) therapies. The analysis of severe VI or blindness was represented by the outcome of both BCVA and VF testing.
Pediatr Blood Cancer
December 2024
Graefes Arch Clin Exp Ophthalmol
February 2025
Purpose: To determine the diagnostic performance and reliability of two pupil perimetry (PP) methods in homonymous hemianopia.
Methods: This cross-sectional monocenter cohort study performed gaze-contingent flicker PP (gcFPP) and a virtual reality version of gcFPP (VRgcFPP) twice on separate occasions in all patients suffering from homonymous hemianopia due to neurological impairment. The main outcomes were (1) test accuracy and (2) test-retest reliability: (1) was measured through area under the receiver operating characteristics curve (AUC) calculation of (VR)gcFPP results with comparators being SAP and healthy controls, respectively; (2) was evaluated by comparing tests 1 and 2 of both methods within patients.